COVID-19 Immunologic Antiviral Therapy With Omalizumab

NCT04720612 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Covid19

Interventions

BIOLOGICAL: Omalizumab
OTHER: Placebo

Sponsor

McGill University Health Centre/Research Institute of the McGill University Health Centre